Have a personal or library account? Click to login
Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis Cover

Therapeutic Drug Monitoring of Venlafaxine and Impact of Age, Gender, BMI, and Diagnosis

Open Access
|Nov 2020

Figures & Tables

Medians of plasma concentrations (VEN and ODV; ODV+VEN) and metabolite to parent drug ratios (ODV/VEN) in patients treated with venlafaxine at the single daily dose of 300 mg (F32 – single episode of MDD; F33 – recurrent episode of MDD)

PatientsVEN [ng/mL]ODV [ng/mL]ODV/VENODV+VEN [ng/mL]
All251823451.85452
Females152553701.85693
Males101482611.75389
Age < 65211323041.92417
Age ≥ 6543455111.55859
F3271282802.00435
F33181983561.74553

Medians of dose-corrected plasma concentrations (DCC) of venlafaxine active moiety (F32 – single episode of MDD; F33 – recurrent episode of MDD)

PatientsDCC [ng/mL/mg]
All281.46
Females162.07
Males121.30
Age < 65241.39
Age ≥ 6542.86
F3281.46
F33201.61
Language: English
Page range: 33 - 37
Submitted on: Feb 28, 2020
Accepted on: Jun 24, 2020
Published on: Nov 18, 2020
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:

© 2020 M. Krivosova, M. Kertys, M. Grendar, I. Ondrejka, I. Hrtanek, I. Tonhajzerova, N. Sekaninova, J. Mokry, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.